Sökning: WFRF:(Vittorio Cannistraci Carlo) >
Serological immune ...
Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients
-
- Álvarez-Fernández, Sheila María (författare)
- San Raffaele Scientific Institute
-
- Barbariga, Marco (författare)
- Lund University,Lunds universitet,Translationell Neurologi,Forskargrupper vid Lunds universitet,Translational Neurology (TNY),Lund University Research Groups
-
- Cannizzaro, Luca (författare)
- Chulalongkorn University
-
visa fler...
-
- Cannistraci, Carlo Vittorio (författare)
- Dresden University of Technology
-
- Hurley, Laura (författare)
- Wayne State University
-
- Zanardi, Alan (författare)
- San Raffaele Scientific Institute
-
- Conti, Antonio (författare)
- San Raffaele Scientific Institute
-
- Sanvito, Francesca (författare)
- San Raffaele Scientific Institute
-
- Innocenzi, Anna (författare)
- San Raffaele Scientific Institute
-
- Pecorelli, Nicolò (författare)
- Vita-Salute San Raffaele University
-
- Braga, Marco (författare)
- Vita-Salute San Raffaele University
-
- Alessio, Massimo (författare)
- San Raffaele Scientific Institute
-
visa färre...
-
(creator_code:org_t)
- 2016-08-10
- 2016
- Engelska 18 s.
-
Ingår i: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 7:48, s. 80059-80076
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
http://www.oncotarge...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- A humoral immune response against aberrant tumor proteins can be elicited in cancer patients, resulting in the production of auto-antibodies (Abs). By serological proteome analysis we identified the surface membrane protein ADAM10, a metalloproteinase that has a role in epithelial-tumor progression and invasion, as a target of the immune response in colorectal cancer (Crc). A screening carried out on the purified protein using testing cohorts of sera (Crc patients n = 57; control subjects n = 39) and validation cohorts of sera (Crc patients n = 49; control subjects n = 52) indicated that anti-ADAM10 auto-Abs were significantly induced in a large group (74%) of colon cancer patients, in particular in patients at stage II and III of the disease. Interestingly, in Crc patients classified as stage III disease, the presence of anti-ADAM10 auto-Abs in the sera was associated with a favourable follow-up with a significant shifting of the recurrence-free survival median time from 23 to 55 months. Even though the ADAM10 protein was expressed in Crc regardless the presence of auto-Abs, the immature/non-functional isoform of ADAM10 was highly expressed in the tumor of anti-ADAM10-positive patients and was the isoform targeted by the auto-Abs. In conclusion, the presence of anti-ADAM10 auto-Abs seems to reflect the increased tumor expression of the immunogenic immature-ADAM10 in a group of Crc patients, and is associated with a favourable prognosis in patients at stage III of the disease.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- ADAM10 metalloprotease
- Autoantibodies
- Colorectal carcinoma
- Immuno-proteomics
- Prognosis
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Álvarez-Fernánde ...
-
Barbariga, Marco
-
Cannizzaro, Luca
-
Cannistraci, Car ...
-
Hurley, Laura
-
Zanardi, Alan
-
visa fler...
-
Conti, Antonio
-
Sanvito, Frances ...
-
Innocenzi, Anna
-
Pecorelli, Nicol ...
-
Braga, Marco
-
Alessio, Massimo
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Oncotarget
- Av lärosätet
-
Lunds universitet